Profile data is unavailable for this security.
About the company
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the development of its DNase platform toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic cancer, which includes pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the available therapeutic options.
- Revenue in USD (TTM)2.52m
- Net income in USD-4.70m
- Incorporated2011
- Employees4.00
- LocationXenetic Biosciences Inc945 Concord St.FRAMINGHAM 01701United StatesUSA
- Phone+1 (781) 778-7720
- Websitehttps://www.xeneticbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 5.52m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
Yubo International Biotech Ltd | 454.29k | -1.42m | 5.52m | 18.00 | -- | -- | -- | 12.16 | -0.0118 | -0.0118 | 0.0038 | -0.0211 | 0.2462 | 0.5986 | 3.49 | 25,238.33 | -82.33 | -- | -- | -- | 80.30 | -- | -334.36 | -- | 0.1707 | -4,795.69 | -- | -- | 479.86 | -- | 0.8224 | -- | -- | -- |
Clearmind Medicine Inc | 0.00 | -8.44m | 5.68m | -- | -- | 1.60 | -- | -- | -12.73 | -12.73 | 0.00 | 0.8728 | 0.00 | -- | -- | -- | -133.31 | -218.20 | -266.82 | -488.96 | -- | -- | -- | -- | -- | -2.60 | 0.0172 | -- | -- | -- | -25.03 | -- | -- | -- |
Eterna Therapeutics Inc | 162.00k | -23.94m | 5.68m | 8.00 | -- | -- | -- | 35.07 | -4.42 | -4.42 | 0.0299 | -1.58 | 0.0035 | -- | 0.2673 | 20,250.00 | -51.20 | -169.05 | -62.39 | -223.00 | -111.11 | -- | -14,765.43 | -682.61 | -- | -10.12 | 10.22 | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
Galmed Pharmaceuticals Ltd | 0.00 | -5.88m | 5.89m | 3.00 | -- | 0.1758 | -- | -- | -24.68 | -24.68 | 0.00 | 22.25 | 0.00 | -- | -- | 0.00 | -44.20 | -45.06 | -52.67 | -50.79 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.31 | -- | -- | -- |
NLS Pharmaceutics AG | 0.00 | -12.17m | 5.97m | 3.00 | -- | -- | -- | -- | -12.75 | -12.75 | 0.00 | -10.90 | 0.00 | -- | -- | 0.00 | -218.86 | -272.62 | -- | -- | -- | -- | -- | -- | -- | -81.34 | -- | -- | -- | -- | 26.21 | -- | -- | -- |
Adial Pharmaceuticals Inc | 0.00 | -12.19m | 6.08m | 4.00 | -- | 0.9536 | -- | -- | -5.26 | -5.30 | 0.00 | 0.9961 | 0.00 | -- | -- | 0.00 | -279.27 | -182.35 | -320.96 | -235.45 | -- | -- | -- | -- | -- | -14.25 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
Enzolytics Inc | 0.00 | -119.19k | 6.22m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
Xenetic Biosciences Inc | 2.52m | -4.70m | 6.24m | 4.00 | -- | 0.8374 | -- | 2.48 | -3.05 | -3.05 | 1.64 | 4.83 | 0.2314 | -- | -- | 630,087.50 | -43.12 | -48.91 | -48.61 | -52.82 | -- | -- | -186.33 | -682.42 | -- | -- | 0.00 | -- | 48.80 | -- | 36.90 | -- | -- | -- |
CeCors Inc | -100.00bn | -100.00bn | 6.24m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
Cardio Diagnostics Holdings Inc | 39.14k | -8.77m | 6.41m | 7.00 | -- | 1.59 | -- | 163.87 | -0.4899 | -0.4899 | 0.0021 | 0.1319 | 0.0073 | -- | 9.13 | 5,591.43 | -163.16 | -- | -268.73 | -- | -- | -- | -22,414.13 | -- | -- | -9.32 | 0.0295 | -- | 1,696.84 | -- | -79.72 | -- | -- | -- |
Intelligent Bio Solutions Inc | 3.11m | -10.16m | 6.50m | 13.00 | -- | 0.6348 | -- | 2.09 | -39.72 | -39.72 | 2.31 | 2.41 | 0.2579 | 1.92 | 8.60 | 239,366.90 | -84.45 | -71.59 | -156.10 | -144.36 | 45.81 | -- | -327.50 | -565.48 | 1.42 | -- | 0.0592 | -- | 147.58 | 596.39 | 4.47 | -- | -- | -- |
TFF Pharmaceuticals Inc | 1.20m | -19.39m | 6.52m | 19.00 | -- | 1.04 | -- | 5.42 | -7.95 | -7.95 | 0.4659 | 1.81 | 0.1043 | -- | 3.51 | 63,293.68 | -168.10 | -79.57 | -212.66 | -83.41 | -- | -- | -1,612.04 | -8,687.66 | -- | -- | 0.00 | -- | 48.01 | -- | 33.13 | -- | -- | -- |
ABVC Biopharma Inc | 136.40k | -11.37m | 6.67m | 16.00 | -- | 0.7808 | -- | 48.93 | -1.78 | -1.78 | 0.0172 | 0.6882 | 0.0114 | -- | 0.4213 | 8,525.00 | -99.79 | -103.38 | -197.79 | -231.54 | -24.11 | 76.25 | -8,762.13 | -2,019.89 | -- | -2.50 | 0.1873 | -- | -84.28 | 85.39 | 35.97 | -- | -- | -- |
Cannabis Bioscience Internatnl Hlgs Inc | 56.94m | 6.94m | 6.78m | 389.00 | 0.0012 | 0.0001 | 0.735 | 0.1191 | 0.5328 | 0.5328 | 4.29 | 4.92 | 0.5917 | 62.81 | 1.45 | 146,384.30 | 7.83 | -- | 11.73 | -- | 31.96 | -- | 13.24 | -- | 0.6856 | 50.75 | 0.0631 | -- | 12.79 | -- | 177.84 | -- | -- | -- |
Viaderma Inc | 17.80m | 2.31m | 6.79m | 75.00 | 0.0003 | 0.00002 | 1.25 | 0.3812 | 16.84 | 16.84 | 129.62 | 255.59 | 0.4126 | 24.69 | 1.21 | 237,331.30 | 5.36 | -- | 6.53 | -- | 28.90 | -- | 12.99 | -- | 2.07 | 5.66 | 0.1718 | -- | -29.15 | -- | -40.70 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Geode Capital Management LLCas of 30 Jun 2024 | 11.99k | 0.78% |
UBS Securities LLCas of 31 Mar 2024 | 3.08k | 0.20% |
JTC Plc /Private Banking/as of 30 Jun 2024 | 2.70k | 0.18% |
Tower Research Capital LLCas of 31 Mar 2024 | 925.00 | 0.06% |
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 11.00 | 0.00% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 1.00 | 0.00% |
Steward Partners Investment Advisory LLCas of 30 Jun 2024 | 0.00 | 0.00% |